RESULTS	Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up \{ hazard ratio ( HR ) [ 95 % confidence interval ( CI ) ] 0.75 ( 0.64-0 .87 ) , P = 0.0003 and 0.85 ( 0.73-1 .00 ) , P = 0.0456 \} for the 7.5 and 15 mg/kg groups , respectively .\